Salivary Gland Cancer
Methodology & AI Transparency ⓘ
Salivary Gland Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C07 for Salivary Gland Cancer clinical workups.
- 3 Typical cash cost range: Workup highlights for Salivary Gland Cancer (C07): multidisciplinary tumor-board planning in Salivary Gland Cancer (C07: (surgery).
- 4 Top reported side effects / signs: Follow-up benchmark in Salivary Gland Cancer: maintaining Comprehensive Metabolic & in Salivary Gland Cancer (C07: Organ Function Panel) within Preserved renal/hepatic clearance (C07).
Ask our AI Specialists anything about Salivary Gland Cancer
What Is Salivary Gland Cancer?
Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer . It is rare. It may not cause any symptoms, or you could notice: A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Salivary Gland Cancer (code C07) is immune-checkpoint evasion [Salivary Gland Cancer C07], Cross-referenced with NIH MeSH (Salivary Gland Neoplasms), which Cancer, Oncology & Supportive Care clinicians address while surveilling Comprehensive Metabolic & in Salivary Gland Cancer (C07: Organ Function Panel) (Preserved renal/hepatic clearance (C07)).
Common Symptoms & Clinical Signs
- • A lump in your ear, cheek, jaw, lip, or inside the mouth
- • Fluid draining from your ear
- • Presentation of Salivary Gland Cancer (C07): unintended weight loss [Salivary Gland Cancer C07]
- • Secondary Salivary Gland Cancer clinical sign: unexplained bleeding, chronic in Salivary Gland Cancer (C07: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Salivary Gland Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C07 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Salivary Gland Cancer (C07: Organ Function Panel) | Preserved renal/hepatic clearance (C07) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Salivary Gland Cancer (C07: Genomic Staging) | Guideline-concordant surveillance (C07) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Salivary Gland Cancer (C07: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C07) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Salivary Gland Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glycopyrrolate Cuvposa, Glyrx-Pf • RxCUI 238212 | Anticholinergic | 85% | $1.2855 | $ 6.98 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Salivary Gland Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer: What a 509-Participant Study Found Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. European journal of cancer (Oxford, England : 1990) • 2024-03-15 • Phase III Randomized Trial | N = 509 | 93/100 | PMID 38309017 ↗ |
| New Insights on Identifying optimal clinical trial candidates for locoregionally advanced: What a 9,468-Participant Study Found N2-3 or T4 NPC patients were ideal candidates for multicenter clinical trials in locoregionally advanced NPC. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2022-02-15 • Phase III Randomized Trial | N = 9,468 | 90/100 | PMID 34971660 ↗ |
| New Insights on Does three-dimensional surgery affect recurrence patterns in patients with: What a 419-Participant Study Found 3D-LG for GC did not differ significantly from 2D-LG in the effects on 3-year recurrence patterns, RFS and OS, which provides more tumor-related evidence for 3D technology. Surgical endoscopy • 2021-01-15 • Phase III Randomized Trial | N = 419 | 87/100 | PMID 31953725 ↗ |
| What the Latest Evidence Really Says About Associations Between Morning Salivary and Blood Cortisol Concentrations in Cortisol concentrations did not differ between adults with OSAS and healthy controls. Frontiers in endocrinology • 2020-01-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 33542703 ↗ |
| Can This Approach Help? Inside the Latest Research on Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced Our results show that adding PD-1 blockade after neoadjuvant chemoradiation increases the pCR rate for patients with LARC and raises no substantial safety concerns. Nature medicine • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39762418 ↗ |
Salivary Gland Cancer Patient Community & “People Like Me” Threads
Filter Salivary Gland Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.